Processa Pharmaceuticals Announces FDA Clears Its Investigational New Drug Application For Phase 2 Trial Of VT-7208 In Chronic Spontaneous Urticaria
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for
The FDA said Processa can test a new medicine on sick patients. This shows the medicine passed early safety checks and the company is moving forward.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.